Circulating Cell-Free DNA in Liquid Biopsies as Potential Biomarker for Bladder Cancer: A Systematic Review.
bladder cancer
blood
cell-free DNA
early diagnosis
liquid biopsy
noninvasive
predictive markers
prognosis
tumor biomarkers
urine
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Mar 2021
22 Mar 2021
Historique:
received:
11
01
2021
revised:
03
03
2021
accepted:
16
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Bladder cancer (BC) is among the most frequent cancer types in the world and is the most lethal urological malignancy. Presently, diagnostic and follow-up methods for BC are expensive and invasive. Thus, the identification of novel predictive biomarkers for diagnosis, progression, and prognosis of BC is of paramount importance. To date, several studies have evidenced that cell-free DNA (cfDNA) found in liquid biopsies such as blood and urine may play a role in the particular scenario of urologic tumors, and its analysis may improve BC diagnosis report about cancer progression or even evaluate the effectiveness of a specific treatment or anticipate whether a treatment would be useful for a specific patient depending on the tumor characteristics. In the present review, we have summarized the up-to-date studies evaluating the value of cfDNA as potential diagnostic, prognostic, or monitoring biomarker for BC in several biofluids.
Identifiants
pubmed: 33810039
pii: cancers13061448
doi: 10.3390/cancers13061448
pmc: PMC8005001
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI17/00495
Organisme : Generalitat Valenciana
ID : ACIF/2017/138
Organisme : Sociedad Española de Trombosis y Hemostasia
Références
J Egypt Natl Canc Inst. 2016 Dec;28(4):235-242
pubmed: 27634416
Front Oncol. 2020 May 19;10:755
pubmed: 32509577
Transl Androl Urol. 2019 Feb;8(1):5-11
pubmed: 30976562
Eur Urol. 2014 Aug;66(2):253-62
pubmed: 24472711
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Clin Genitourin Cancer. 2015 Feb;13(1):e37-49
pubmed: 25178641
Clin Cancer Res. 2019 Feb 1;25(3):967-976
pubmed: 30352907
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Chem. 2019 Jul;65(7):927-936
pubmed: 30988170
Cancer Sci. 2019 May;110(5):1771-1779
pubmed: 30887605
Bladder Cancer. 2018 Jan 20;4(1):41-48
pubmed: 29430506
Cancer Discov. 2018 Jul;8(7):812-821
pubmed: 29848605
Curr Protoc Hum Genet. 2008 Apr;Chapter 10:Unit 10.11
pubmed: 18428421
Cancer Biomark. 2012;11(2-3):89-98
pubmed: 23011155
Sci Rep. 2018 Oct 2;8(1):14707
pubmed: 30279572
Diagnostics (Basel). 2020 Apr 13;10(4):
pubmed: 32294884
Sci Rep. 2017 Apr 3;7(1):583
pubmed: 28373672
Urology. 2005 Dec;66(6 Suppl 1):4-34
pubmed: 16399414
Cancers (Basel). 2019 Nov 06;11(11):
pubmed: 31698791
Clin Cancer Res. 2017 Nov 1;23(21):6487-6497
pubmed: 28760909
Oncotarget. 2017 May 7;8(34):56398-56407
pubmed: 28915599
Eur Urol. 2018 Apr;73(4):535-540
pubmed: 28958829
Anal Chim Acta. 2019 Aug 30;1068:1-10
pubmed: 31072469
Genome Med. 2020 Feb 28;12(1):23
pubmed: 32111235
Acta Cytol. 2019;63(6):449-455
pubmed: 31091522
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Clin Biochem. 2019 Feb;64:60-63
pubmed: 30528938
J Clin Lab Anal. 2019 Feb;33(2):e22668
pubmed: 30175467
J Cancer. 2019 Jul 8;10(17):4038-4044
pubmed: 31417648
Clin Cancer Res. 2018 Dec 15;24(24):6212-6222
pubmed: 30093454
Clin Chem. 2020 Jan 1;66(1):188-198
pubmed: 31811000
Sci Rep. 2018 Jan 30;8(1):1917
pubmed: 29382943
Urol Oncol. 2019 Jan;37(1):86-96
pubmed: 30446454
PLoS One. 2015 Oct 16;10(10):e0140712
pubmed: 26474073
Sci Transl Med. 2018 Nov 7;10(466):
pubmed: 30404863
Methods Mol Biol. 2019;1909:13-27
pubmed: 30580420
Eur Urol. 2020 Apr;77(4):420-433
pubmed: 31563503
Clin Transl Med. 2020 Jan 14;9(1):4
pubmed: 31938901
J Clin Oncol. 2019 Jun 20;37(18):1547-1557
pubmed: 31059311
Expert Rev Mol Diagn. 2006 Mar;6(2):153-63
pubmed: 16512776
Biomol Detect Quantif. 2019 Mar 18;17:100087
pubmed: 30923679
Am J Cancer Res. 2017 Nov 01;7(11):2318-2332
pubmed: 29218253
Eur Urol. 2017 Jun;71(6):961-969
pubmed: 28069289
ESMO Open. 2019 Nov;4(6):
pubmed: 32149725
Cancer. 2018 May 15;124(10):2115-2124
pubmed: 29517810
N Engl J Med. 2018 Nov 01;379(18):1754-1765
pubmed: 30380390
Transl Androl Urol. 2017 Dec;6(6):1090-1110
pubmed: 29354496
Diagnostics (Basel). 2020 Jun 30;10(7):
pubmed: 32629823
Urol Oncol. 2013 Nov;31(8):1744-50
pubmed: 23141783
Mol Oncol. 2020 Aug;14(8):1670-1679
pubmed: 32471011
Clin Biochem. 2009 May;42(7-8):729-31
pubmed: 19166828
BJU Int. 2019 Sep;124(3):532-544
pubmed: 31077629
Urol Int. 2016;96(1):25-31
pubmed: 26338254
Urol Oncol. 2015 Feb;33(2):66.e25-31
pubmed: 25037483
Cancers (Basel). 2019 Jun 11;11(6):
pubmed: 31212602
Investig Clin Urol. 2016 Mar;57(2):106-12
pubmed: 26981592
Clin Genitourin Cancer. 2019 Jun;17(3):e704-e711
pubmed: 31088707
Cancer. 2020 Jun 1;126(11):2597-2606
pubmed: 32208524
Biomarkers. 2017 Nov;22(7):654-660
pubmed: 27998182
Eur Urol. 2016 Jul;70(1):75-82
pubmed: 26803478
Cancers (Basel). 2020 Apr 02;12(4):
pubmed: 32252299
PLoS One. 2020 Apr 6;15(4):e0231058
pubmed: 32251424
J Vis Exp. 2017 Jan 5;(119):
pubmed: 28117781
Photodiagnosis Photodyn Ther. 2019 Jun;26:131-133
pubmed: 30822568
Eur J Hum Genet. 2016 Aug;24(8):1167-74
pubmed: 26757983
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
EBioMedicine. 2018 Aug;34:76-84
pubmed: 30078735
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Eur Urol Oncol. 2020 Oct;3(5):695-699
pubmed: 31412004
Oncotarget. 2018 Feb 7;9(18):14354-14365
pubmed: 29581849
Transl Androl Urol. 2020 Jun;9(3):1222-1231
pubmed: 32676405
Cancer Sci. 2021 Jan;112(1):168-177
pubmed: 33027843
BJU Int. 2000 Jul;86 Suppl 1:111-22
pubmed: 10961281